Advanced Cancer Clinical Trial
Official title:
Valproate (Valproic Acid) and Etoposide for Patients With Progressive, Relapsed or Refractory Neuronal Tumors and Brain Metastases
Primary Objective:
- Determine the interindividual range and median of individual maximum tolerated doses of
valproic acid administered as one time evening dose in conjunction with a dose oral
etoposide (50 mg/m2/day for children, but only 25mg/m2/day for adults to start) for
four different age groups.
Secondary Objectives:
- Determine the qualitative and quantitative toxicity and reversibility of toxicity of
valproic acid in conjunction with oral etoposide,
- To investigate the clinical pharmacokinetics of valproic acid when given in conjunction
with oral etoposide,
- To describe quality of life of patients with relapsed, or progressive central and
peripheral nervous system tumors when treated with oral valproic acid and etoposide,
- To observe and describe the response pattern of progressive central nervous system
tumors treated with oral valproic acid and etoposide,
- To observe and describe event free survival time and overall survival time of patients
with relapsed, or progressive central nervous system tumors when treated with oral
valproic acid and etoposide,
- To determine if histone deacetylase activity and topoisomerase expression in
lymphocytes of patients is related to valproic acid levels, and
- To determine, if the individual maximal tolerated dose (iMTD) depends on the initial
performance status of the patient in the beginning of the treatment.
Study Drugs:
Etoposide is designed to block cell growth by breaking the DNA, which may cause the cells to
die.
Valproic acid was first designed as an anti-seizure medication. It was also found to change
cancer cells and make them more sensitive to etoposide.
Screening Tests:
Before you start treatment on this study, you will have "screening tests". These tests help
your doctor decide if you are eligible to take part in this study.
- Your medical history will be reviewed.
- You will have a physical exam.
- You will be asked how well you are able to perform the normal activities of daily
living (performance status evaluation).
- You will complete a questionnaire about your activities or daily living. The
questionnaire will take about 5 to 10 minutes to complete.
- Blood (about 2-3 tablespoons) will be drawn for routine tests. This routine blood draw
may include a pregnancy test for women who are able to have children. To be eligible to
take part in this study, the pregnancy test must be negative.
- Urine may be collected to check for metabolic disease. This urine sample may include a
pregnancy test for women who are able to have children. To be eligible to take part in
this study, the pregnancy test must be negative.
- You will have a magnetic resonance imaging (MRI) or computed tomography (CT) scan.
- If your doctor thinks it is necessary, you may have additional blood and/or urine
tests.
Dose Escalation:
When you begin the study, you will begin receiving the lowest dose level of valproic acid.
Every week, the dose will be increased. This will continue until the maximum tolerated dose
(MTD) is found. Once the MTD is found, you will continue to receive that dose level of
valproic acid while you are on study. However, if your doctor thinks it is necessary, this
dose level could be lowered.
If you are a child (less than or equal to 18 years of age), the amount of etoposide that you
take while on study will not change.
If you are an adult (more than 18 years of age), your will receive a low dose of etoposide
while the MTD of valproic acid is being found. After the MTD of valproic acid is found, your
dose of etoposide will be increased every week until the MTD is found. However, if your
doctor thinks it is necessary, this dose level could be lowered.
Study Drug Administration:
You will receive valproic acid and etoposide every evening in pill form.
If you have difficulty swallowing the pills, etoposide can be given in the evening in liquid
form. Valproic acid can be given in liquid form, divided in 2 doses per day, 1 in the
morning and 1 in the evening.
Study Visits During Dose Escalation:
While your valproic acid or etoposide medication is being increased, every week you will
have a physical exam and blood (about 2-3 tablespoons)and urine will be collected for
routine tests.
Every other month, you will have CT or MRI scans to check the status of the disease. You may
have these tests and procedures more often if your doctor thinks it is necessary.
Study Visits After Maximum Tolerated Dose (MTD):
Every month, you will have a physical exam, and blood (about 2-3 tablespoons) and urine will
be collected for routine tests.
Every other month, you will have CT or MRI scans to check the status of the disease.
Every 6 months, a portion of the blood or urine collected for routine tests will be used for
a pregnancy test for women who are able to have children.
-You may have these tests and procedures more often if your doctor thinks it is necessary.
Length of Study:
You may remain on study for up to 2 years. You will be taken off study if the disease gets
worse or intolerable side effects occur.
End-of-Study Visit:
Once you are off study, you will have an end-of-study visit. At this visit, the following
tests and procedures will be performed:
- You will have a physical exam.
- Blood (about 2-3 tablespoons) and urine will be collected for routine tests.
- If your doctor thinks it is necessary, you will have a CT or MRI to check the status of
the disease.
Follow-Up:
Once you are off study, you will be contacted by telephone once a year to check the status
of the disease. The phone call will take 2-3 minutes.
This is an investigational study. Etoposide is FDA approved and commercially available.
Valproic acid is FDA approved and commercially available for the treatment of seizures. The
use of these drugs together is investigational. Up to 120 patients will take part in this
multicenter study. Up to 100 will be enrolled at M. D. Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |